The presence of coagulopathy as part of the systemic inflammatory response syndrome is a characteristicfeature of severe coronavirus disease 2019 (COVID-19). Hematological changes (increased D-dimer [DD],prolonged activated partial thromboplastin clotting time [APTT] and prothrombin time [PT], highfibrinogen levels) have been observed in hospitalized patients with COVID-19, which characterizethe risk of thrombotic events. Against the background of COVID-19 there is endothelial dysfunction,hypoxia and pulmonary congestion, mediated by thrombosis and microvascular occlusion. Up to71.4% of patients who died from COVID-19 had disseminated intravascular coagulation syndrome,compared with only 0.6% of survivors. The main manifestation of COVID-19-associated coagulopathyis a significant increase in DD without a decrease in platelet count or prolongation of APTT and PT,indicating increased thrombin formation and the development of local fibrinolysis. An increase in DDlevels of more than 3–4 times was associated with higher in-hospital mortality. Therefore, COVID-19requires assessment of the severity of the disease for further tactics of thromboprophylaxis. The need forcontinued thromboprophylaxis, or therapeutic anticoagulation, in patients after inpatient treatment fortwo weeks using imaging techniques to assess of thrombosis assessment.